What is HC Wainwright’s Estimate for Prothena Q4 Earnings?

Prothena Co. plc (NASDAQ:PRTA) – HC Wainwright issued their Q4 2025 EPS estimates for Prothena in a report issued on Friday, February 21st. HC Wainwright analyst A. Fein anticipates that the biotechnology company will post earnings per share of ($0.58) for the quarter. HC Wainwright has a “Buy” rating and a $48.00 price objective on the stock. The consensus estimate for Prothena’s current full-year earnings is ($4.04) per share.

Prothena (NASDAQ:PRTA) last issued its earnings results on Thursday, February 20th. The biotechnology company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.06). Prothena had a negative return on equity of 22.67% and a negative net margin of 90.50%. The firm had revenue of $2.12 million during the quarter, compared to analysts’ expectations of $7.53 million.

Other research analysts have also issued research reports about the stock. Oppenheimer raised their price target on shares of Prothena from $58.00 to $62.00 and gave the company an “outperform” rating in a report on Friday, February 7th. Bank of America reduced their target price on shares of Prothena from $26.00 to $22.00 and set a “neutral” rating on the stock in a report on Thursday, December 19th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Prothena in a research report on Friday, February 21st. StockNews.com raised Prothena from a “sell” rating to a “hold” rating in a research report on Monday. Finally, Royal Bank of Canada decreased their target price on Prothena from $24.00 to $20.00 and set a “sector perform” rating for the company in a research report on Friday, February 21st. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $45.83.

Prothena Price Performance

Prothena stock opened at $14.63 on Monday. Prothena has a 12 month low of $11.70 and a 12 month high of $31.03. The company has a market cap of $787.23 million, a price-to-earnings ratio of -6.36 and a beta of 0.08. The stock’s 50-day moving average is $14.40 and its 200-day moving average is $16.68.

Institutional Trading of Prothena

Several large investors have recently modified their holdings of PRTA. Two Sigma Investments LP lifted its stake in shares of Prothena by 265.4% in the fourth quarter. Two Sigma Investments LP now owns 38,394 shares of the biotechnology company’s stock worth $532,000 after acquiring an additional 27,887 shares in the last quarter. Rafferty Asset Management LLC raised its position in shares of Prothena by 24.8% in the 4th quarter. Rafferty Asset Management LLC now owns 77,672 shares of the biotechnology company’s stock valued at $1,076,000 after purchasing an additional 15,442 shares in the last quarter. ProShare Advisors LLC raised its position in shares of Prothena by 29.5% in the 4th quarter. ProShare Advisors LLC now owns 14,524 shares of the biotechnology company’s stock valued at $201,000 after purchasing an additional 3,312 shares in the last quarter. Man Group plc boosted its stake in shares of Prothena by 90.7% during the 4th quarter. Man Group plc now owns 77,430 shares of the biotechnology company’s stock valued at $1,072,000 after buying an additional 36,824 shares during the last quarter. Finally, Millennium Management LLC increased its stake in shares of Prothena by 9.3% in the fourth quarter. Millennium Management LLC now owns 123,005 shares of the biotechnology company’s stock worth $1,704,000 after buying an additional 10,467 shares during the last quarter. 97.08% of the stock is currently owned by institutional investors and hedge funds.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.